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Arsenic is an established lung carcinogen, however, the
carcinogenic mechanisms are currently under investigation.
Phosphorylation of the epidermal growth factor receptor (EGFR)
has been reported with arsenic exposure in bladder cells. EGFR is
a tyrosine kinase transmembrane receptor that regulates impor-
tant processes in carcinogenesis, including cell survival, cell cycle
progression, tumor invasion, and angiogenesis. We investigated
the mechanisms of EGFR pathway activation by levels of arsenic
relevant to human exposure scenarios both in vitro using cultured
lung epithelial cells, and in lung tumors samples from New
England Lung Cancer Study participants. Toenail arsenic levels
were used as an internal biomarker of arsenic exposure. Our
in vitro data suggest that arsenic increases levels of the EGFR
ligand, heparin binding-EGF, and activate EGFR phosphorylation
in the lung. Downstream of EGFR, arsenic exposure increased
pERK and cyclin D1 levels. These effects were inhibited by
treatment of cultured cells with the EGFR tyrosine kinase
inhibitor, Tarceva (erlotinib). In a consecutive series of human
lung tumor specimens, pEGFR protein levels were higher in
subjects with elevated toenail arsenic levels compared to those
with low exposure (odds ratio adjusted for other factors, OR 4.1
(95% conﬁdence interval 1.1–15.6) (p 5 0.04). These data suggest
that arsenic exposure may stimulate EGFR pathway activation in
the lung. Moreover, the tumors that arise in arsenic-exposed
individuals also exhibit signs of EGFR pathway dysregulation.
Further work is needed to assess the clinical utility of targeting the
EGFR pathway in subgroups of lung cancer patients who have
been exposed to elevated levels of arsenic.
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Arsenic is an established lung, skin and bladder carcinogen
(IARC, 2004), however the precise mechanisms by which
arsenic acts in these tissues are currently under investigation
(Abernathy et al., 1999). Arsenic has been shown to potentiate
the genotoxicity of other organic mutagen-carcinogens,
particularly polycyclic aromatic hydrocarbons (PAHs) includ-
ing benzo(a)pyrene (BAP) (ATSDR, 1999; Rossman, 2003).
Rats treated with arsenic and BAP sustained 84% of their DNA
adduct burden after 27 days, compared with only a 13% burden
sustained for rats treated with BAP alone (Tran et al., 2002).
Additionally, there is compelling evidence that arsenic
carcinogenesis is synergistic with tobacco (IARC, 2004).
Chronic arsenic exposure from consumption of contaminated
drinking water has been associated with lung cancer risk in
epidemiologic studies conducted in Taiwan (20þ mg/l 3
years), Chile (200–400 lg/l, 2–5lM), and Bangladesh
(> 599 lg/l, 8lM) (reviewed in Navarro Silvera and Rohan,
2007). In Chile, subjects born during the years when
Antofagasta city water levels were approximately 875 lg/l,
12lM and exposed in early childhood had a lung cancer
standardized mortality ratio of 7.0 (95% conﬁdence interval
[CI] 5.4–8.9) (Smith et al., 2006). Primarily due to geologic
sources of contamination, drinking water arsenic levels are
above the current recommended maximum contaminant level
of 10 lg/l in several areas of the United States including the
Northeast and Southwest (Karagas et al., 2002; NRC, 2001). In
these U.S. populations chronic consumption of arsenic-
contaminated drinking water over a period of years has been
associated with elevated risk of skin cancer and of bladder
cancer among smokers (Karagas et al., 2001; Steinmaus et al.,
2003; Karagas et al., 2004). While high levels of arsenic
consumption are clearly associated with lung cancer risk and
interact with smoking, the risk for exposed U.S. populations
and the involvement of smoking remains understudied (Celik
et al., 2008).
Lung cancer is the most common type of cancer worldwide,
accounting for 12.6% of all incident cancer cases. Lung cancer
accounted for more deaths than any other type of cancer in the
United States in 2007. Of all cancer deaths, 31% were due to
lung cancer in men and 26% were due to lung cancer in women
(ACS, 2007). The overall ﬁve year survival rate is only 15%,
and varies dramatically by stage (49% for localized, 16% for
regional and 2% for distant) (Jemal et al., 2004). Unfortu-
nately, distant disease is the most common stage at presentation
(ACS, 2007). Tobacco smoking is responsible for the majority
of lung cancer cases (87%) (ACS, 2007). Passive exposure to
tobacco smoke is associated with a reported 20–25% increased
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use, please contact journals.permissions@oxfordjournals.org.risk of lung cancer (Travis et al., 2004). Since 15–20% of lung
cancers in women and 5–10% of lung cancers in men occur in
never smokers, it is also important to consider other etiologic
factors and carcinogenic mechanisms in nonsmokers (Zaridze
et al., 1998).
The mechanisms of arsenic carcinogenesis are an active area
of investigation. At a biochemical level, arsenic can disrupt zinc
ﬁnger containing protein structures (Witkiewicz-Kucharczyk
and Bal, 2006) and binds to sulfhydryl groups and cysteinyl
residues (Suzuki et al., 2008). Arsenic induces chromosomal
abberations, aneupolidy, and micronuclei formation, but does
not directly interact with DNA and is not a strong mutagen
(Rossman, 2003). Arsenic also induces formation of reactive
oxygen and nitrogen species (Smith et al., 2001). The known
biological effects of arsenic include endocrine disruption,
altered DNA repair, altered cell signaling, altered cell cycle
kinetics, and alterations in proliferative response (reviewed in
Rossman, 2003).
The epidermal growth factor receptor (EGFR) is a tyrosine
kinase transmembrane receptor in the ErB family of receptors
expressed on the surface of epithelial cells (Kari et al. 2003).
A previous study demonstrated EGFR activation in lung cells
at very high levels of arsenite (500lM) (Wu et al. 1999).
Further work has demonstrated that both sodium arsenite and
monomethylarsonous acid (MMA(III)) also induced EGFR
phosphorylation in bladder cell lines (Eblin et al., 2007;
Simeonova et al., 2002). EGFR is overexpressed in lung
tumors and precancerous lesions, and is known to induce tumor
formation in animal studies. This overexpression occurs in
many tumors without gene ampliﬁcation, supporting the
hypothesis that exposures can modify EGFR levels (Hilbe
et al., 2003).
EGFR regulates important processes in carcinogenesis,
including cell survival, cell cycle progression, tumor invasion,
and angiogenesis. Ligands including EGF, transforming
growth factor-a (TGF-a) and Amphiregulin (Areg) bind to
EGFR activating signal transduction pathways that upregulate
transcription factors leading to growth stimulation (Lin et al.,
2001). The EGFR pathway mediates its effects by regulating
the expression of a number of target genes (Kari et al., 2003).
We hypothesize that some of the biologic effects of arsenic
exposure may mechanistically involve modifying signaling
through the EGFR pathway. Several lines of evidence indicate
that cyclin D1 is a downstream regulator in the EGFR pathway
(Reissmann et al., 1999; Lin et al., 2001; Moriuchi et al., 2001;
Petty et al., 2004). EGFR tyrosine kinase inhibitors (EGFR-
TKI) suppress cell growth, arrest cells in G1, and decrease
cyclin D1 expression in cell cultures. Therapeutic concen-
trations of EGFR-TKI were associated with decreased cyclin
D1 and tumor necrosis in EGFR-TKI responsive patients in
a small lung clinical trial (Petty et al., 2004). Cell culture
studies show that EGF stimulates Ras/MAPK activity and
cyclin D1 expression (Moriuchi et al., 2001). EGFR contains
a transactivation domain and can bind to AT-rich consensus
sites, including those found in cyclin D1, and activate
transcription (Lin et al., 2001). Chromatin immunoprecipita-
tion assays demonstrated that nuclear EGFR is associated with
the cyclin D1 promoter in vivo (Lin et al., 2001). Arsenic
exposure is associated with elevated cyclin D1 levels in some,
but not all cell culture models (Rossman et al., 2001; Souza
et al., 2001; Vogt and Rossman, 2001; Wei et al., 2002).
Defects in cell cycle control may contribute to tumorigenesis
and tumor progression by allowing cells to overcome cell cycle
checkpoints. Cell cycle arrest normally occurs in response to
a DNA lesion to allow repair of the damaged DNA and
therefore, lack of arrest decreases repair efﬁciency and ﬁdelity
(Sancar et al., 2004). Overexpression of cyclin D1 results in
more cyclin D1- cdk4 or 6 heterodimeric complexes that
phosphorylate the growth suppressor pRb. Inactivation allows
Rb to release its repression of the transcription factors E2F and
DP allowing them to induce transcription of cyclin E and other
genes that promote cell cycle progression (Fu et al., 2004).
Therapeutic efﬁcacy with EGFR-TKIs that block EGFR
activation is observed clinically and are a recent Food and Drug
Administration (FDA)–approved treatment for non–small cell
lung cancer (NSCLC) (reviewed in Herbst et al., 2004).
Despite this, responsiveness to this class of drugs varies
dramatically between patients, and reliable predictors of the
most appropriate patient subgroups remain to be identiﬁed.
Motivated by the availability of these EGFR pathway
inhibitors, this study of lung epithelial cells investigates the
mechanisms involved in EGFR pathway activation by arsenic
exposure at contamination levels relevant to the U.S.
population. We test the efﬁcacy of EGFR inhibitors in blocking
arsenic-induced pathway activation and then assess the
relationship between EGFR alterations in human lung tumors
and biomarker-based arsenic exposure status.
MATERIALS AND METHODS
Cell culture. Human bronchial epithelial cells (Beas-2B, ATCC; Rock-
ville, MD) were grown to postconﬂuence in 6- or 12-well plates (Corning
Costar; Corning, NY) on VPM matrix, as previously described (Andrew and
Barchowsky, 2000; Andrew et al., 2001a, b; Barchowsky et al., 2002). The
cultures were maintained in LHC-9 medium (Bioﬂuids Inc.; Rockville, MD) at
37C under an atmosphere of 5% CO2/95% air. Cells were then switched to
KBM medium without EGF (Clonetics; Cambrex Bio Science Walkersville,
Inc., Walkersville, MD) 72 h before treatment. Cells were exposed to sodium
arsenite (Sigma, St Louis, MO) (0.01–10lM, which is equivalent to 0.75–750
lg/l) for a period of 24 h before harvesting for RNA isolation or protein.
Tarceva (erlotinib) was a kind gift from OSI pharmaceuticals (Farmingdale,
NY). EGF (50 ng/ml) was used as a positive control (Sigma). Cycloheximide
(CHX) (30 lg/ml) (Sigma) was used to inhibit protein synthesis.
Gene expression analysis. RNA was harvested using Trizol reagent
(Gibco/BRL, Life Technologies, Gaithersburg, MD) followed by DNase
digestion using DNAfree (Ambion, Inc., Austin, TX) according to the
manufacturer’s instructions and quantitated by spectrophotometric absorbance
at 260 nm. Real-time reverse transcription PCR (RT-PCR) was performed
using gene speciﬁc primers and reagents (ABI, Foster City, CA) using the ABI
PRISM sequence detection system and software. Brieﬂy, total RNA (0.5 lg)
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with oligo-dT and dNTPs according to the instructions provided with the
Qiagen Omniscript kit (Qiagen; Valencia, CA). Samples were reverse
transcribed in a MJ Research PTC-100 thermocycler (MJ Research, Inc.,
Watertown, MA) for 60 min at 44C and the reaction terminated by heating to
95C for 10 min. Expression of HBEGF (heparin-binding EGF-like growth
factor; ABI, GenBank GeneID 1839), Cyclin D1 (GenBank GeneID 595),
TGF-a (GenBank 7039), and amphiregulin (GenBank 374) were assessed by
real-time PCR using 10 ng total RNA, 400nM primers, 200nM probe, and
TaqMan Universal PCR Master Mix (ABI). The ﬁgures are representative of at
least two experiments performed with n ¼ 3 individual cultures. Relative
quantitation was performed using a standard curve consisting of serial dilutions
of pooled sample cDNA from the same source as the test RNA with each plate.
Relative expression levels of each gene were normalized to 18s rRNA or
GAPDH (ABI).
Protein levels. The levels of EGFR, p-EGFR, and Cyclin D1 proteins were
assessed by immunoblotting using sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) to resolve proteins from whole cell lysates. Each
ﬁgure is representative of a minimum of two experiments performed with an
n ¼ 3 individual cultures. Cells were rinsed with ice cold stop buffer (10 mmol/l
Tris-HCl, pH 7.4, 10 mmol/l ethylenediaminetetraacetic acid, 5 mmol/l
EGTA, 100 mmol/l NaF, 200 mmol/l sucrose, 100 lmol/l Na-orthovanadate, 5
pyrophosphate, 4 lg/ml leupeptin, 4 lg/ml soybean trypsin inhibitor, 1 mmol/l
benzamidine, 20 lmol/l calpain inhibitor 1, 100 mU/ml aprotinin, and 100 lmol/l
phenylmethylsulphonylﬂouride).Thestopbufferwasthenreplacedwithaminimal
volume of 23 SDS-PAGE buffer (62.5mM Tris-HCl, pH 6.8, 10% glycerol, 2%
SDS,5%b-mercaptoethanol,0.05%(wt/vol)bromophenolblue).Thelysateswere
boiled for 5 min and clariﬁed by centrifugation at 13,000 rpm for 10 min. Equal
amounts of cell lysate were then resolved by electrophoresis on 8–12% SDS-
polyacrylamide gels. Electrophoresis was performed at constant voltage (200 V),
then the resolved proteins were transferred from the polyacrylamide gel to
polyvinylidene diﬂuoride membrane (PVDF, Immobilon-P, Millipore, Bedford,
MA) by semi-dry transfer (Hoeffer Semiphor, San Fransisco, CA) for 1 h at
constant current (32 mA/minigel) using transfer buffer (25mM Tris, 192mM
glycine, 20% [vol/vol] methanol, 0.01% SDS). To eliminate nonspeciﬁc
interactions of antibodies with the membrane, the PVDF membrane was blocked
withTTBS(10mMTris-HCl,pH8.0,150mMNaCl,0.05%Tween-20)containing
5% milk (7.5 g/150 ml) for 1 h at room temperature or overnight at 4C.
Membranes were incubated with the primary EGFR, p-EGFR antibody speciﬁc to
Tyr 1173, pSTAT1 (Tyr701) (Cell Signaling Technology, Danvers, MA) diluted
1:1000, or the primary Cyclin D1 antibody diluted 1:500, the pAKT (Ser473), or
the pERK 1/2 (Thr202/Tyr204) antibodies diluted 1:1000 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) in TTBS overnight at 4C. B-actin was
used as a loading control diluted 1:100,000 in TTBS for 1 h (Sigma). The
membranes were washed three times with TTBS. The EGFR and p-EGFR
membranes were incubated with horseradish peroxidase (HRP)–linked goat
anti-rabbit IgG (Santa Cruz Biotechnology, Inc.) 1:2000 in TTBS with 1% milk
(0.3g/30ml)for1hatroomtemperature.TheCyclinD1membranewasincubated
with HRP-linked goat anti-mouse (Santa Cruz Biotechnology, Inc.) 1:3000 in
TTBS with 1% milk (0.3 g/30 ml). The Secondary for B-actin was HRP-linked
goat anti-mouse at 1:6000 (Bio-Rad Laboratories, Inc., Richmond, CA). After
three washes with TTBS, protein bands were visualized by enhanced
chemiluminescence using the Amersham ECL Plus Western Blotting Detection
system (GE Healthcare, Piscataway, NJ) and ﬁlm (Lumi-Film, Roche Molecular
Biochemicals, Indianapolis, IN).
Lung tumors. Lung cancer cases include individuals with histologically
conﬁrmed NSCLC, newly diagnosed between 1/1/05 and 12/1/06 who were
25–74 years of age and residents of the New England Lung Cancer Study area
(ten contiguous counties of New Hampshire and Vermont) at the time of
diagnosis. We obtained signed consent to access tumor specimens from these
cases and received institutional human subjects approval. Immunohistochem-
istry was performed on a slide cut from a master lung cancer Tissue
Microarray block containing tissue samples from 68 subjects using an
antibody to p-EGFR or EGFR (Cell Signaling Technology, Danvers, MA).
The intensity and percent of cells with membranous staining in each tumor
was scored by the study pathologist, who was blinded to the arsenic exposure
status of the subjects. For logistic regression analysis, positive p-EGFR
staining was deﬁned as more than 20% of cells staining at greater than 1þ
intensity, which represented the top 10th percentile of staining. Toenail
clipping samples collected at the time of interview were analyzed for arsenic
(As, lg/g) by collision cell inductively coupled plasma mass spectrometry
(ICP-MS) (7500c, Agilent, Santa Clara, CA). At the Dartmouth Trace
Metals core facility. The detection limit for arsenic was approximately 0.003
lg/g.
Statistical analysis. Statistical analysis for gene expression and immuno-
blotting was performed using the ANOVA procedure with Newman-Keuls
post-test (Figs. 3–5) or unpaired, two-sided t-test (Fig. 6) in GraphPad PRISM
(GraphPad Software, La Jolla, CA). We considered p values less than 0.05 to
be statistically signiﬁcant. We conducted logistic regression analyses for
positive vs. negative p-EGFR staining lung tumors in relation to arsenic
exposure. Analyses were adjusted for age, gender, tumor histology, and pack-
years of smoking using SAS 9.1.3 (SAS Institute, Cary, NC).
RESULTS
Our experiments consistently showed EGFR degradation
following EGF, but not arsenic treatment (Figs. 1 and 2, row
1 EGFR). Treatment with the cycloheximide to inhibit
protein synthesis further supported the observation that
EGFR levels stay steady following arsenic exposure, while
they degrade within the 3 h of EGF treatment. Protein
synthesis inhibition alone (cycloheximide only) does not
affect EGFR levels, suggesting that the receptor is not
degraded unless activated by EGF (Fig. 1A). Figure 1B
shows increased levels of the phosphorylated form of EGFR
following treatment with arsenic (1.3, 5, and 10lM) or the
positive control, EGF.
Cells treated with 5lM sodium arsenite showed increased
levels of EGFR phosphorylation (p-EGFR at Tyr 1173) at
3 and 5 h by immunoblot (Fig. 2, row 2, p-EGFR). The
classical ligand, EGF induced EGFR phosphorylation and
degradation of the receptor. We did not see changes in other
phosphorylation sites in response to arsenic, including Tyr 992,
845, 1068 (data not shown). This effect was inhibited by
pretreatment with the FDA-approved EGFR-TKI drug Tarceva
at clinically achievable doses. The total level of EGFR protein
in Beas-2B human bronchial epithelial cells was modestly
increased following arsenic exposure (Fig. 2A). We observed
a signiﬁcant increase in EGFR mRNA levels with EGF, but not
with arsenic exposure (data not shown).
We then assessed the effects of arsenic on the cell cycle
regulator cyclin D1, since it can be regulated by the EGFR
pathway (Lin et al., 2001). Levels of cyclin D1 protein were
elevated following 3 h arsenic and EGF (Fig. 2A, row 1
CCND1). The positive control, EGF also induced a large
increase in cyclin D1 levels. Pretreatment with the EGFR-TKI,
Tarceva blocked the effects of arsenic (3 h) and EGF on cyclin
D1. As reported previously, arsenic exposure increased cyclin
D1 gene expression levels to those that were signiﬁcantly
higher than controls at 5lM for 3 h (Fig. 3).
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tion via one of its classical ligands. As shown in Figure 4A,
arsenic induced the expression of the EGFR pro-ligand HB-
EGF, as did EGF itself. Neither TGF-a (Fig. 4B), nor Areg
(Fig. 4C) levels were modiﬁed by arsenic exposure at 4 h, yet
they were induced by the positive control EGF.
We also investigated several possible signal transduction
pathways immediately downstream from EGFR. We did not
observe a dose-responsive increase in p-STAT1 with arsenic
exposure. The positive control EGF did increase pSTAT1
levels (Fig. 5, row 1). Likewise, AKT was not signiﬁcantly
phosphorylated in response to either arsenic or EGF treatment,
and actually decreased at the 1 and 2.5lM arsenic doses (Fig.
5, row 2). Arsenic exposure led to increased protein levels of p-
ERK that were strongest at the 5lM dose (Fig. 5, row 3).
We then investigated the relation between arsenic exposure
and EGFR pathway activation by immunohistochemistry in
a consecutive series of human lung tumors. Figure 6 shows
a signiﬁcantly higher percent of cells staining for phospho-
EGFR/EGFR in the human lung tumor specimens for subjects
with elevated toenail arsenic concentration (as an internal
biomarker of exposure) (n ¼ 68, p ¼ 0.04). Although EGFR
levels were slightly elevated in the high arsenic group, the
difference was not statistically signiﬁcant. We also assessed the
association between high levels of p-EGFR staining and
arsenic exposure by logistic regression, with adjustment for
tumor histology, AJCC stage classiﬁcation, age, gender, and
pack-years of smoking. Arsenic exposure (> 0.05 lg/g) was
associated with higher p-EGFR staining OR 4.1 (95% CI 1.1–
15.6) (based on upper 75th percentile, n ¼ 22) in comparison to
subjects with low exposure (As   0.05 lg/g, n ¼ 46).
DISCUSSION
EGFR overexpression and pathway activation is observed in
lung tumors and induces tumor formation in animal models.
Some of these effects may be mediated through induction of
the cell cycle promoter, cyclin D1 (Petty et al., 2003). Our data
demonstrate for the ﬁrst time that the EGFR pathway is
activated in the human lung in response to the moderate levels
of arsenic that are observed in contaminated U.S. drinking
water. We used toenail arsenic levels as a long-term internal
biomarker of exposure that is highly correlated with drinking
water levels (Karagas et al., 2000). Our in vitro studies
demonstrate that arsenic-induced phosphorylation of this
receptor is prevented by pretreatment with the EGFR-TKI
erlotinib/Tarceva, an FDA approved treatment for NSCLC.
Our data are consistent with the EGFR activation that was
observed previously following very high level arsenic exposure
(500lM) in a study of lung cells (Wu et al. 1999). Another
study reported that arsenic (50lM) phosphorylated both EGFR
and ERK in urothelial cells, however they did not see activa-
tion of the Tyr 1173 auto-phosphorylation site (Simeonova
FIG. 1. EGFR levels following arsenic or EGF exposure. (A) Cells were exposed to 5lM arsenic or EGF (50 ng/ml) 3 h, with or without the protein synthesis
inhibitor CHX (30 lg/ml) for 1, 2, or 3 h. Immunoblots were performed using antibodies to EGFR and B-actin. Densitometry was performed to quantitate the
protein levels. (B) Cells were exposed to 1, 5, 10 lM arsenic or EGF (50 ng/ml) for 3 h. Immunoblots were performed using antibodies to p-EGFR and B-actin.
Densitometry was performed to quantitate the protein levels.
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levels following long-term incubation with MMA(III) and
EGFR phosphorylation within an hour of exposure (Eblin
et al., 2007). Arsenic-exposed keratinocytes (200lM) showed
AKT, but not EGFR activation (Souza et al., 2001), however,
EGFR activation was observed in another keratinocyte study
with either 100lM arsenite or 800lM arsenate (Tanaka-
Kagawa et al. 2003). Arsenic trioxide (20lM) also increased
p21 expression in A431 cells via activation of the EGFR/ERK
pathway (Huang et al., 2006; Liu and Huang, 2006).
We observed that activation of EGFR signaling by the
classical endogenous ligand, EGF, triggers rapid receptor
degradation. In contrast, arsenic induced phosphorylation of
the receptor at a more subtle level than EGF and the receptor
was not degraded in response to activation by arsenic. Previous
studies have documented that EGFRs are mono-ubiquinated
soon after activation and transported to lysosomes for
degradation (Lin et al., 2006; Shen et al., 2007). EGF-triggered
receptor degradation is mediated by cbl, which recognizes
EGFR phosphorylation and acts as the E3 ubiquitin ligase. The
cdc42-associated tyrosine kinase ACK1, later colocalizes with
EGFR following receptor phosphorylation on vesicles during
endocytosis and acts as a ubiquitin-binding protein (Shen et al.,
2007). Our phospho-speciﬁc EGFR antibody detected the
phosporylated form of the receptor. Despite an increase in
EGFR mRNA levels with EGF treatment, this rapid receptor
protein degradation causes the total EGFR protein level in the
cell to decrease. Consistent with our in vitro studies, the lungs
of arsenic-exposed lung cancer patients showed slightly higher
total levels of EGFR, while pEGFR levels were signiﬁcantly
higher than nonexposed patients.
Classical EGFR ligands include HB-EGF, TGF-a and Areg
(Kari et al., 2003). Arsenic exposure increased HB-EGF levels,
suggesting that this may be an upstream mediator of EGFR
pathway activation. We did not observe any effect of arsenic on
TGF-a or Areg. Identifying the speciﬁc downstream target
genes that are regulated by the EGFR pathway is an area of
FIG. 3. Cells were exposed to arsenic (5lM) for 3 h and Cyclin D1
(CCND1) gene expression was assessed using real-time PCR. Bars represent
the mean and SD. *Statistically signiﬁcant from control group, or from arsenic
group (*p < 0.05).
FIG. 2. EGFR tyrosine kinase inhibition by Tarceva blocks arsenic induced
p-EGFRandcyclinD1.(A)Cellswereexposedtoarsenic(5lM)for30min–5h,
with or without 3lM of the EGFR-TKI Tarceva (erlotinib). The classical ligand
EGF(50 ng/ml)7hwas usedasa positivecontrol.Immunoblots wereperformed
using antibodies to EGFR, phospho-EGFR (p-EGFR), cyclin D1 (CCND1) and
B-actin. (B) Densitometry was performed on this and other immunoblots (n ¼ 3)
to quantitate the protein levels at 3 h. Bars represent the mean and SD of the ratio
ofp-EGFRtoEGFR,aswellasCyclinD1.(C)Theratioofp-EGFRtoEGFR,as
well as Cyclin D1 protein levels quantitated by densitometry for EGF treated
samples. *Statistically signiﬁcant from control group, or from arsenic group
(*p < 0.05, **p < 0.01, ***p < 0.001).
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cell types, both arsenic and EGF exposure increased p-ERK
levels downstream of p-EGFR (Huang et al., 2006; Liu and
Huang, 2006; Tanaka-Kagawa et al., 2003). These increases
were inhibited by EGFR-TKI treatment. Several studies
provide evidence that cyclin D1 is regulated by EGFR
signaling (Lin et al., 2001; Moriuchi et al., 2001; Petty
et al., 2004; Reissmann et al., 1999). Our data strongly support
the hypothesis that arsenic increases cyclin D1 levels in part via
EGFR pathway activation, and that this effect is inhibited by
EGFR-TKI treatment. Previous studies have also suggested
a role for Src in EGFR signaling to downstream target genes
(Huang et al., 2006; Simeonova et al., 2002). Recent evidence
also suggested that EGFR can regulate vascular endothelial
FIG. 4. Arsenic induces HB-EGF, but not the other EGFR ligands TGF-a
and Areg. Cells were exposed to arsenic (5lM) for 4 h. EGF (50 ng/ml) was
used as a positive control. RNA was harvested and real-time PCR assays were
performed for expression of (A) HB-EGF, (B) TGF-a, (C) amphiregulin
(AREG). Bars represent the mean and SD. *Statistically signiﬁcant from
control group, or from arsenic group (*p < 0.05, **p < 0.01, ***p < 0.001).
FIG. 5. Arsenic induces phosphorylation of ERK and STAT, but not
AKT. Cells were exposed to arsenic (1, 2.5, 5lM) for 5 h. The classical ligand
EGF (50 ng/ml) was used as a positive control. Western blots were performed
using antibodies to pSTAT1, p-ERK1/2, pAKT, or B-actin.
FIG. 6. Toenail arsenic is associated with p-EGFR protein levels in
human lung tumors. Immunohistochemical staining and scoring were
performed on lung tumor tissue samples from 68 consenting cases using an
antibody to p-EGFR or EGFR. The percent of cells staining with 1þ intensity
was plotted by subject’s toenail level of arsenic, as an internal biomarker of
exposure (n ¼ 68 subjects, upper 75th percentile As,  0.05 lg/g vs. > 0.05 lg/
g). Bars represent the mean and standard error. Statistically signiﬁcant
difference between high and low arsenic exposure (*p ¼ 0.04).
ARSENIC ACTIVATES LUNG EGFR SIGNALING 355growth factor (VEGF) expression via HIF-1a and Sp1.
Although the hypothesized EGFR regulated genes, including
VEGF, as well as p21 and HIF-1a were induced by arsenic, we
did not observe EGFR-TKI inhibition of this effect (Huang
et al., 2006; Liu and Huang, 2006; Pore et al., 2006).
Human plasma levels of the EGFR extracellular domain
were signiﬁcantly increased with arsenic exposure in a Bangla-
deshi population (Li et al., 2007). Likewise, we observed
higher EGFR and p-EGFR protein levels in the lung tumor
tissue of arsenic-exposed compared to nonexposed patients.
Our in vitro work demonstrating a dose-responsive increase in
total EGFR protein and mRNA levels further support this
ﬁnding and suggest that arsenic-induced activation of EGFR
pathway signaling in lung epithelial cells can be inhibited by
treatment with EGFR-TKIs (Gschwind et al., 2004; Pao and
Miller, 2005). The EGFR signaling in response to repeated
drinking water arsenic exposure could lead to chronic EGFR
pathway activation that could feed tumor development. This
mechanism of carcinogenesis due to chronic pathway activa-
tion may be akin to that found in the lung tumors of individuals
who have speciﬁc activating mutations in the tyrosine kinase
domain of the EGFR (Paez et al., 2004; Pedersen et al., 2005).
Additional studies are required to conﬁrm this hypothesis.
Limitations of our lung cancer study include a small patient
population and an observational study design. Nevertheless,
EGFR tyrosine kinase inhibition has shown clinical utility in
patient response and improved survival speciﬁcally among
subsets of patients who have EGFR driven tumors (Clark et al.,
2006). Data from the current study suggest that arsenic-
associated lung tumors may also have EGFR pathway
activation. Further work is needed to assess the clinical utility
of targeting the EGFR pathway in subgroups of lung cancer
patients who have been exposed to elevated levels of arsenic.
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